Search results
Results from the WOW.Com Content Network
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, ... for $25 million cash and $150 million in stock. [28] ...
Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In this article we will take a look at whether hedge funds think Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a good investment right now. We check hedge fund and billionaire investor sentiment ...
Alnylam (ALNY) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Year World market cap Number of listed companies Millions of US$ % of GDP; 1975 1,149,245 27.2 14,577 1980 2,525,736 29.6 17,273 1985 4,684,978 47.0 20,555
Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.